Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.
Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.
Das
Amitava
A
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Mukherjee
Priyabrata
P
Singla
Sumit K
SK
Guturu
Praveen
P
Frost
Megan C
MC
Mukhopadhyay
Debabrata
D
Shah
Vijay H
VH
Patra
Chitta Ranjan
CR
D049109:Cell Proliferation / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods*; D004705:Endocytosis / Q000187:drug effects; D006046:Gold / Q000737:chemistry*; D055166:Hepatic Stellate Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D007700:Kinetics; D053768:Metal Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D050997:Nanomedicine / Q000379:methods; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009569:Nitric Oxide / Q000008:administration & dosage*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D010641:Phenotype; D026423:S-Nitroso-N-Acetylpenicillamine / Q000494:pharmacology; D012822:Silicon Dioxide / Q000737:chemistry*; D013056:Spectrophotometry, Ultraviolet
D020030:Nitric Oxide Donors; D009569:Nitric Oxide; D006046:Gold; D012822:Silicon Dioxide; D026423:S-Nitroso-N-Acetylpenicillamine